Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates

15.08.2022 - - Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - ...

Related Keywords

United States ,Boston ,Massachusetts ,Axel Bolte ,Inozyme Pharma ,Stefan Riley ,Matt Pera ,Kurt Gunter ,Joseph Schlessinger ,Demetrios Braddock ,Yale University ,Inozyme Pharma Inc ,Beginngs Consortium ,Nasdaq ,Exchange Commission ,Development Rd Expenses ,Rady Children Institute For Genomic Medicine ,European Calcified Tissue Society Congress ,Data Safety Monitoring Board ,Natural History ,Clinical Trial ,Publications Peer Reviewed ,Experimental Dermatology ,Rady Children ,Genomic Medicine ,Whole Genome Sequencing ,Debt Facility ,Financial Guidance ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Consolidated Statements ,Months Ended June ,